Biblio Discovery — Demo Discovery Service

20 hasil untuk "Sandra Robrecht"

Menampilkan 1–20 · 0,64 detik · RSS

  1. Artikel Jurnal

    Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)

    Sonia Jaramillo; Andreas Agathangelidis; Christof Schneider dkk.

    Haematologica, Vol. 105 No. 11 · 2019 · Inggris · DOAJ Scopus

    Almost one-third of all patients with chronic lymphocytic leukemia (CLL) express stereotyped B cell receptor immunoglobulins (BcR IG) and can be assigned to distinct subsets, each with a particular BcR IG. The largest stereotyped subsets are #1, #2, #4 and #8, associated with specific…

  2. Artikel Jurnal

    Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients

    Johannes Bloehdorn; Julia Krzykalla; Karlheinz Holzmann dkk.

    Haematologica, Vol. 107 No. 3 · 2021 · Inggris · DOAJ Scopus

    Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) can induce long-term remissions in patients with chronic lymphocytic leukemia. Treatment efficacy with Bruton's tyrosine kinase inhibitors was found similar to FCR in untreated chronic lymphocytic leukemia patients with a…

  3. Artikel Jurnal Teks lengkap

    Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial

    Paula Cramer; Julia v. Tresckow; Sandra Robrecht dkk.

    Haematologica, Vol. 106 No. 2 · 2020 · Inggris · DOAJ Scopus

    The introduction of targeted agents has revolutionized the treatment of chronic lymphocytic leukemia but only few patients achieve complete remissions and minimal residual disease negativity with ibrutinib monotherapy. This multicenter, investigator-initiated phase-II study evaluates a sequential…

    Juga tersedia di: DOAJ

  4. Artikel Jurnal

    Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

    Othman Al-Sawaf; Can Zhang; Hyun Yong Jin dkk.

    Nature Communications, Vol. 14 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Data on long-term outcomes and biological drivers associated with depth of remission after BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are limited. In this open-label parallel-group phase-3 study, 432 patients with previously untreated CLL were…

  5. Artikel Jurnal

    Chronic lymphocytic leukemia with IGH::BCL3‐translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape

    Cosima Drewes; Cristina López; Juan Emilio Martinez‐Manjón dkk.

    HemaSphere, Vol. 10 No. 5 · 2026 · Inggris · DOAJ Scopus

    Abstract Approximately 1% of chronic lymphocytic leukemia (CLL) cases harbor a translocation juxtaposing the immunoglobulin heavy chain (IGH) and B‐cell lymphoma 3 (BCL3) loci. Aiming at comprehensive molecular characterization of IGH::BCL3‐positive B‐cell neoplasms, we here investigated samples…

  6. Artikel Jurnal

    IGLV3‐21R110 and ibrutinib treatment: Results from the double‐blind, randomized, placebo‐controlled GCLLSG CLL12 trial in early‐stage CLL

    Deyan Y. Yosifov; Sandra Robrecht; Adam Giza dkk.

    HemaSphere, Vol. 10 No. 6 · 2026 · Inggris · DOAJ Scopus

    Abstract IGLV3‐21R110 is a point mutation enabling autonomous B‐cell receptor (BCR) signaling in chronic lymphocytic leukemia (CLL). It has been associated with shorter time to first treatment and overall survival, but its effects have not been evaluated in phase 3 clinical trials or in patients…

  7. Artikel Jurnal

    Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription

    Jennifer Edelmann; Karlheinz Holzmann; Eugen Tausch dkk.

    Haematologica, Vol. 105 No. 5 · 2020 · Inggris · DOAJ Scopus

    To identify genomic alterations contributing to the pathogenesis of high-risk chronic lymphocytic leukemia (CLL) beyond the well-established role of TP53 aberrations, we comprehensively analyzed 75 relapsed/refractory and 71 treatment-naïve high-risk cases from prospective clinical trials by single…

  8. Artikel Jurnal

    Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)

    Nadine Kutsch; Jasmin Bahlo; Sandra Robrecht dkk.

    HemaSphere, Vol. 4 No. 1 · 2020 · Inggris · DOAJ Scopus

    Abstract. Fludarabine, cyclophosphamide and rituximab (FCR) was compared to bendamustine and rituximab (BR) in an international, randomized, open label, phase 3 trial in 561 previously untreated, fit patients with chronic lymphocytic leukemia (CLL) without del (17p). Primary endpoint was…

  9. Artikel Jurnal Teks lengkap

    First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

    Barbara F. Eichhorst; Carsten Utoft Niemann; Arnon Philip Kater dkk.

    New England Journal of Medicine · 2023 · Inggris · OpenAlex Scopus

    Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking. Download a PDF of the Research Summary. In a phase 3, open-label trial, we…

  10. Artikel Jurnal

    Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia

    Johannes Bloehdorn; Andrejs Braun; Amaro Taylor-Weiner dkk.

    Nature Communications, Vol. 12 No. 1 · 2021 · Inggris · DOAJ Scopus

    Chronic lymphocytic leukemia has been studied using multiple levels of omics data. Here, the authors use exome sequencing, SNP, protein and gene expression data to identify distinct biologic tumor subtypes with heterogeneous prognostic impact after chemo- or immunochemotherapy.